Author Resources

General Information

Adapted Checklists

Disclosure Policy

Updated Disclosure Policy: CJASN and JASN Editors have concluded that a common disclosure policy is in the interest of our readers and our authors. Authors are required to divulge all potential financial conflicts of interest on all manuscripts submitted to either journal, as consistent with the recommendations from the International Committee of Medical Editors (ICMJE). The disclosures as described below should include all sources of revenue paid (or promised to be paid) directly to you or to your institution on your behalf over the 36 months prior to submission of the work.

Full disclosures to be reported should include all of the following regardless of whether the authors perceive a direct or actual conflict with the submitted work:
• Relationships with pharmaceutical firms, device firms or other entities (such as small business start-ups, research support, employment contracts, consultancy, advisory boards, speaker bureaus, membership on Board of Directors, stock ownership and/or stock options).
• Ownership of intellectual property in any way related to the work under consideration, including, but not limited to, patents and patent submissions.
• Financial relationships of any kind with entities in the biomedical arena.

Process:
• In the initial submission, providing complete disclosures for all authors is the responsibility of the corresponding author.
• The disclosure statement should be placed in the main text of the manuscript immediately following the Acknowledgements.
• For all manuscripts invited to submit a revision, each author must complete their own ICMJE form for Disclosure of Potential Conflicts of Interest. This form will be sent automatically to each co-author through the system. This is a condition for further consideration of the revised manuscript.
• If needed, the initial disclosure statement will be edited by the Editors to include the “Disclosure Statement” generated by the ICMJE form for each author.

Failure to comply with the above disclosure statement requirements could lead to the following:
• Incomplete disclosure of potential conflicts of interest may lead to rejection of submitted manuscripts.
• For conflicts identified after publication, JASN and CJASN reserve the right to sanction authors for their failure to accurately and completely report the potential financial conflicts of interest. The sanctions may range from issuing a correction, reporting to the authors’ institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

ICMJE Form for Authors     [PDF]

Visual Abstracts

The CJASN Editorial Team will create a Visual Abstract for all accepted original articles.  They will develop the Visual Abstract to fit with the approved CJASN style and format.  Authors will have the opportunity to review, and edit as necessary, the Visual Abstract prior to publication. CJASN may use the Visual Abstract in any Tweets and in any other appropriate materials.

The CJASN Visual Abstract Primer explains the CJASN approach to Visual Abstracts including referencing the standard templates that CJASN first used when Visual Abstracts were introduced.  While the template styles are still in place, the fluid nature of content has provided CJASN with the opportunity to be more creative with the design of Visual Abstracts thereby better serving readers and authors.  

Editorial Office
Mary L. Chang, ELS, Managing Editor
American Society of Nephrology
1401 H St, NW, Suite 900
Washington, DC 20005
Phone: (202) 570-2059
Email: mchang@cjasn.org